Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. Issue 12 (15th October 2022)

• Record Type: Journal Article
• Authors: Panaite, Lorena; Wu, Qian "Vicky"; Voutsinas, Jenna; Mullane, Erin; Chow, Victor A.; Lynch, Ryan C.; Ujjani, Chaitra S.; Smith, Stephen D.; Gopal, Ajay K.; Poh, Christina; Iovino, Lorenzo; Turtle, Cameron J.; Maloney, David G.; Till, Brian G.; Gauthier, Jordan; Shadman, Mazyar
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 12(2022)
• Page Start: 2918
• Page End: 2922
• Publication Date: 2022-10-15
• Subjects: Immunotherapy -- lymphoma and hodgkin disease -- immunotherapeutic approaches; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2095632
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Cytopenias are important but less studied adverse events following chimeric antigen receptor-engineered T cell (CAR-T) therapy. In our analysis of patients with large cell lymphoma who received axicabtagene ciloleucel (axi-cel), we sought to determine the rate and risk factors of clinically significant short term cytopenias defined as grade ≥3 neutropenia, anemia, or thrombocytopenia, or treatment with growth factors or blood product transfusions between days 20–30 after axi-cel. Fifty-three pts received axi-cel during the study period and severe cytopenias were observed in 32 (60%) pts. Significant cytopenias were more common in non-responders (stable or progressive disease) vs. responders (partial or complete response) (100% vs. 70%; p = .01). In the multivariable model, platelet transfusion within a month before leukapheresis, number of red blood cell and platelet transfusions between leukapheresis to lymphodepletion, pre-lymphodepletion absolute neurophil count, pre-lymphodepletion lactate dehydrogenase, and number of dexamethasone treatments after CAR-T were significantly associated with severe cytopenias after axi-cel.